- $4.61m
- $6.92m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 601.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -68932.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.12 | 0.05 | 0.21 | 0.09 | 0.01 | n/a | n/a | -49.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Directors
- Brady Granier PRE (48)
- Lourdes Felix CEO (53)
- Thomas Welch EVP (49)
- Kent Emry IND (52)
- Joseph Galligan IND (61)
- Louisa Ingargiola IND (47)
- Louis Lucido IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 28th, 2008
- Public Since
- August 31st, 2010
- No. of Shareholders
- 160
- No. of Employees
- 5
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 16,099,432
- Address
- 2390 East Orangewood Avenue, Suite 570, ANAHEIM, 92806
- Web
- https://www.biocorrx.com/
- Phone
- +1 7144624880
- Auditors
- Marcum LLP
Upcoming Events for BICX
Q2 2025 BioCorRx Inc Earnings Release
Similar to BICX
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
What is the Biocorrx share price?
As of Today at 19:35 UTC, shares in Biocorrx are trading at $0.29. This share price information is delayed by 15 minutes.
How has the Biocorrx share price performed this year?
Shares in Biocorrx last closed at $0.29 and the price had moved by -80.5% over the past 365 days. In terms of relative price strength the Biocorrx share price has underperformed the S&P500 Index by -81.78% over the past year.
What are the analyst and broker recommendations for Biocorrx?
There is no consensus recommendation for this security.
Find out moreWhat is the Biocorrx dividend yield?
Biocorrx does not currently pay a dividend.
Does Biocorrx pay a dividend?
Biocorrx does not currently pay a dividend.
When does Biocorrx next pay dividends?
Biocorrx does not currently pay a dividend.
How do I buy Biocorrx shares?
To buy shares in Biocorrx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biocorrx?
As of the previous close price of $0.29, shares in Biocorrx had a market capitalisation of $4.61m.
Where are Biocorrx shares listed?
Here are the trading details for Biocorrx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BICX
What kind of share is Biocorrx?
Based on an overall assessment of its quality, value and momentum Biocorrx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biocorrx share price forecast for 2025?
The analyst consensus target price for shares in Biocorrx is $5.10. That is 1679.48% above the last closing price of $0.29.
Analysts covering Biocorrx currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Biocorrx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocorrx. Over the past six months, its share price has underperformed the S&P500 Index by -1.11%.
As of the last closing price of $0.29, shares in Biocorrx were trading -59.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biocorrx PE Ratio?
The Biocorrx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biocorrx?
Biocorrx's management team is headed by:
- Brady Granier - PRE
- Lourdes Felix - CEO
- Thomas Welch - EVP
- Kent Emry - IND
- Joseph Galligan - IND
- Louisa Ingargiola - IND
- Louis Lucido - IND